Non-alcoholic steatohepatitis (NASH), which involves inflammation and damage to liver cells, can develop from this illness. The most prevalent kind of liver cancer, hepatocellular carcinoma (HCC), and ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

Tempest Therapeutics (TPST) announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug ...

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

PVT patients exhibited elevated levels of cfDNA and histone-DNA complexes, and reduced DNase activity. This pattern persisted ...

(NASDAQ: ICAD) ("iCAD” or the "Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast ...

【导读】ME2在癌症发生过程中经常升高，可能是癌症治疗的靶点，它催化苹果酸转化为丙酮酸。然而，控制ME2活性的过程目前仍不清楚。11月11日，贵州医科大学罗鹏教授研究团队在期刊《Cell Death&Disease》上发表了研究论文，题为“PRMT1 ...

Namodenoson has already shown potential in other significant indications, such as hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), ...

HCC risk prediction may be poorly reported and biased for individuals with nonviral chronic liver disease. Hepatocellular carcinoma (HCC) risk prediction models are generally based on studies with ...

Learn how personalised treatments are providing new hope with tailored therapies offering better outcomes for patients ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...